Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection Against Heterologous Influenza A Viruses

Overview

Journal J Microbiol Biotechnol

Specialties Biotechnology
Microbiology

Date 2020 Dec 2

PMID 33263336

Citations 5

Authors

Chaewon Kwak

Quyen Thi Nguyen

Jaemoo Kim

Tae-Hwan Kim

Haryoung Poo

Affiliations

Soon will be listed here.

Abstract

Vaccination is the most effective way to prevent influenza virus infections. However, conventional vaccines based on hemagglutinin (HA) have to be annually updated because the HA of influenza viruses constantly mutates. In this study, we produced a 3M2e-3HA2-NP chimeric protein as a vaccine antigen candidate using an expression system. The vaccination of chimeric protein (15 μg) conferred complete protection against A/Puerto Rico/8/1934 (H1N1; PR8) in mice. It strongly induced influenza virus-specific antibody responses, cytotoxic T lymphocyte activity, and antibody-dependent cellular cytotoxicity. To spare the dose and enhance the cross-reactivity of the chimeric, we used a complex of poly-γ-glutamic acid and alum (PGA/alum) as an adjuvant. PGA/alum-adjuvanted, low-dose chimeric protein (1 or 5 μg) exhibited higher cross-protective effects against influenza A viruses (PR8, CA04, and H3N2) compared with those of chimeric alone or alum-adjuvanted proteins in vaccinated mice. Moreover, the depletion of CD4 T, CD8 T, and NK cells reduced the survival rate and efficacy of the PGA/alum-adjuvanted chimeric protein. Collectively, the vaccination of PGA/alum-adjuvanted chimeric protein induced strong protection efficacy against homologous and heterologous influenza viruses in mice, which suggests that it may be a promising universal influenza vaccine candidate.

Citing Articles

Inserting CTL Epitopes of the Viral Nucleoprotein to Improve Immunogenicity and Protective Efficacy of Recombinant Protein against Influenza A Virus.

Shuklina M, Stepanova L, Ozhereleva O, Kovaleva A, Vidyaeva I, Korotkov A Biology (Basel). 2024; 13(10).

PMID: 39452110 PMC: 11505154. DOI: 10.3390/biology13100801.

Influenza and Universal Vaccine Research in China.

Li J, Zhang Y, Zhang X, Liu L Viruses. 2023; 15(1).

PMID: 36680158 PMC: 9861666. DOI: 10.3390/v15010116.

Production of polyglutamic acid-like mucilage protein by Peribacillus simplex strain 8h.

Sato S, Ichiyanagi N, Sugiyama K, Aburai N, Fujii K Folia Microbiol (Praha). 2022; 68(1):101-113.

PMID: 35947243 DOI: 10.1007/s12223-022-01000-4.

Targeting Antigens for Universal Influenza Vaccine Development.

Nguyen Q, Choi Y Viruses. 2021; 13(6).

PMID: 34073996 PMC: 8225176. DOI: 10.3390/v13060973.

Animal Models for Influenza Research: Strengths and Weaknesses.

Nguyen T, Rollon R, Choi Y Viruses. 2021; 13(6).

PMID: 34071367 PMC: 8228315. DOI: 10.3390/v13061011.

References

Vemula S, Sayedahmed E, Sambhara S, Mittal S . Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017; 16(11):1141-1154. PMC: 6005355. DOI: 10.1080/14760584.2017.1379396. View

Kim Y, Lee Y, Kim M, Lee Y, Kim K, Ko E . Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice. Front Immunol. 2017; 8:1730. PMC: 5727122. DOI: 10.3389/fimmu.2017.01730. View

Tutykhina I, Esmagambetov I, Bagaev A, Pichugin A, Lysenko A, Shcherbinin D . Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. PLoS One. 2018; 13(1):e0191574. PMC: 5788337. DOI: 10.1371/journal.pone.0191574. View

MacLeod M, David A, Jin N, Noges L, Wang J, Kappler J . Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One. 2013; 8(4):e61775. PMC: 3629017. DOI: 10.1371/journal.pone.0061775. View

Wang W, Huang B, Jiang T, Wang X, Qi X, Gao Y . Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One. 2013; 7(12):e52488. PMC: 3528677. DOI: 10.1371/journal.pone.0052488. View

Zheng M, Luo J, Chen Z . Development of universal influenza vaccines based on influenza virus M and NP genes. Infection. 2013; 42(2):251-62. DOI: 10.1007/s15010-013-0546-4. View

Lai J, Choo J, Tan W, Too C, Oo M, Suter M . TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants. Sci Rep. 2017; 7(1):9923. PMC: 5577143. DOI: 10.1038/s41598-017-10265-6. View

Misplon J, Lo C, Gabbard J, Tompkins S, Epstein S . Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine. 2010; 28(36):5817-27. DOI: 10.1016/j.vaccine.2010.06.069. View

Black R, Rota P, Gorodkova N, Klenk H, Kendal A . Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol. 1993; 74 ( Pt 1):143-6. DOI: 10.1099/0022-1317-74-1-143. View

10.

Gerhard W, Mozdzanowska K, Zharikova D . Prospects for universal influenza virus vaccine. Emerg Infect Dis. 2006; 12(4):569-74. PMC: 3294695. DOI: 10.3201/eid1204.051020. View

11.

Park S, Si Y, Kim J, Song M, Kim S, Kim E . Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology. 2016; 498:36-43. DOI: 10.1016/j.virol.2016.08.010. View

12.

Jegaskanda S, Job E, Kramski M, Laurie K, Isitman G, De Rose R . Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. 2013; 190(4):1837-48. DOI: 10.4049/jimmunol.1201574. View

13.

McElhaney J, Beran J, Devaster J, Esen M, Launay O, Leroux-Roels G . AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013; 13(6):485-96. DOI: 10.1016/S1473-3099(13)70046-X. View

14.

Rimmelzwaan G, Fouchier R, Osterhaus A . Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007; 18(6):529-36. DOI: 10.1016/j.copbio.2007.11.002. View

15.

Tan G, Krammer F, Eggink D, Kongchanagul A, Moran T, Palese P . A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012; 86(11):6179-88. PMC: 3372189. DOI: 10.1128/JVI.00469-12. View

16.

Goff P, Eggink D, Seibert C, Hai R, Martinez-Gil L, Krammer F . Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One. 2013; 8(11):e79194. PMC: 3819267. DOI: 10.1371/journal.pone.0079194. View

17.

Wohlbold T, Nachbagauer R, Margine I, Tan G, Hirsh A, Krammer F . Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine. 2015; 33(29):3314-21. PMC: 4472732. DOI: 10.1016/j.vaccine.2015.05.038. View

18.

Simonsen L, Clarke M, Schonberger L, Arden N, Cox N, Fukuda K . Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis. 1998; 178(1):53-60. DOI: 10.1086/515616. View

19.

Grebe K, Yewdell J, Bennink J . Heterosubtypic immunity to influenza A virus: where do we stand?. Microbes Infect. 2008; 10(9):1024-9. PMC: 2584237. DOI: 10.1016/j.micinf.2008.07.002. View

20.

Yang P, Wang W, Gu H, Li Z, Zhang K, Wang Z . Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice. Antiviral Res. 2014; 111:1-7. DOI: 10.1016/j.antiviral.2014.08.008. View